ProQR Therapeutics
PRQR
47 hedge funds and large institutions have $31.7M invested in ProQR Therapeutics in 2024 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 15 reducing their positions, and 5 closing their positions.
1,175% more call options, than puts
Call options by funds: $880K | Put options by funds: $69K
11% more capital invested
Capital invested by funds: $28.6M → $31.7M (+$3.09M)
0.18% more ownership
Funds ownership: 21.17% → 21.36% (+0.18%)
2% less funds holding
Funds holding: 48 → 47 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
40% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$658K |
| 2 |
Morgan Stanley
New York
|
+$369K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$168K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$129K |
| 5 |
PFM
Privium Fund Management
Amsterdam,
Netherlands
|
+$97K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$519K |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$388K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$101K |
| 4 |
Two Sigma Advisers
New York
|
-$82.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$46.3K |
PRQR Hedge Fund Activity: Q3 2024 in Review
47 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q3 2024, worth a combined $31.7M — up 11% from $28.6M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of PRQR and 4 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 9 added.
The largest buyer was Schonfeld Strategic Advisors, adding an estimated $658K. The largest seller was Deutsche Bank, cutting an estimated $519K.
- 47 institutional investors held ProQR Therapeutics (PRQR) as of Q3 2024, down from 48 in Q2 2024.
- Funds reported $31.7M of ProQR Therapeutics stock for Q3 2024, up 11% quarter-over-quarter.
- 4 funds opened new ProQR Therapeutics positions in Q3 2024 and 5 closed out, a net change of -1 holder.
- The largest ProQR Therapeutics buyer in Q3 2024 was Schonfeld Strategic Advisors, an estimated $658K added.
- The largest ProQR Therapeutics seller in Q3 2024 was Deutsche Bank, an estimated $519K sold.
Based on aggregated 13F filings for Q3 2024.